These results suggest that exposure to HBOT significantly decreases iNOS activity/expression and indicate that ERK1/2 and Akt are involved in HBOT-downregulated iNOS activity/expression in T1DM patients. The gene discussed is MAPK3; the disease is type 1 diabetes mellitus.